Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Ocrevus Coverage Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy 02-2026

    Ocrevus and Ocrevus Zunovo (ocrelizumab) Coverage Criteria

    Customize your policy alerts

    Sign up for Hawaii Medical Service Association (HMSA) Policy 02-2026 alerts

    Get alerted when Policy 02-2026 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA prior authorization and coverage of Ocrevus and Ocrevus Zunovo for members with specified forms of multiple sclerosis. Coverage requires applicable clinical criteria, prescribing by or consultation with a neurologist, and compliance with other policy requirements.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyOcrevus and Ocrevus Zunovo (ocrelizumab) Coverage Criteria
    Policy CodePolicy 02-2026
    Change TypeNo material clinical or coverage change
    Effective DateJun 26, 2026
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required for the requested therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsAuthorization period
    3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered indication groups
    NeurologistPrescriber specialty
    RequiredPrior authorization

    Coverage Criteria

    Relapsing Forms of Multiple Sclerosis

    Authorization of 12 months may be granted when the member has the qualifying diagnosis.

    Relapsing forms of multiple sclerosis: Member has been diagnosed with a relapsing form of multiple sclerosis, including relapsing-remitting disease or secondary progressive disease for those who continue to experience relapse.

    Authorization period is 12 months.

    Clinically Isolated Syndrome

    Authorization of 12 months may be granted for treatment of the qualifying condition.

    Clinically isolated syndrome: Member has clinically isolated syndrome of multiple sclerosis.

    Authorization period is 12 months.

    Primary Progressive Multiple Sclerosis

    Authorization of 12 months may be granted for treatment of the qualifying condition.

    Primary progressive multiple sclerosis: Member has primary progressive multiple sclerosis.

    Authorization period is 12 months.

    Continuation Therapy

    Authorization of 12 months may be granted for members with an indication listed in the coverage criteria who are experiencing disease stability or improvement while receiving the requested drug.

    Continuation therapy: Member has an indication listed in the coverage criteria and is experiencing disease stability or improvement while receiving the requested drug.

    Authorization period is 12 months.

    Other Criteria

    Additional criteria apply to use of the requested drug.

    No concomitant disease-modifying MS therapy: Member will not use the requested drug concomitantly with other disease-modifying multiple sclerosis agents.

    Ampyra and Nuedexta are not disease-modifying agents for this rule.

    Pediatric use: For a pediatric member less than 18 years of age, benefits of treatment outweigh risks.less than 18 years of age

    Authorization may be granted when benefits outweigh risks.

    The requested drug must not be used concomitantly with another disease-modifying multiple sclerosis agent. Ampyra and Nuedexta are exceptions to this restriction because they are not disease-modifying therapies.

    Initial Therapy Criteria

    Initial Therapy: Relapsing Forms of MS

    Authorization of 12 months may be granted to members diagnosed with a relapsing form of multiple sclerosis.

    Relapsing MS diagnosis: Member has a relapsing form of multiple sclerosis, including relapsing-remitting disease or secondary progressive disease for those who continue to experience relapse.

    Authorization period is 12 months.

    Initial Therapy: Clinically Isolated Syndrome

    Authorization of 12 months may be granted for treatment of clinically isolated syndrome of multiple sclerosis.

    Clinically isolated syndrome: Member has clinically isolated syndrome of multiple sclerosis.

    Authorization period is 12 months.

    Initial Therapy: Primary Progressive MS

    Continuation Therapy

    Continuation Therapy

    Authorization of 12 months may be granted for members with an indication listed in Section C.

    Continuation response: Member is experiencing disease stability or improvement while receiving the requested drug.

    The member must also have an indication listed in the coverage criteria. Authorization period is 12 months.

    Provider Requirements and Action Items

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for OCREVUS. Submit the HMSA specialty drug policy fax form and supporting documentation through the HMSA medical specialty drug policy process.

    Documentation Required

    Neurologist Involvement

    OCREVUS must be prescribed by or in consultation with a neurologist.

    Documentation Required

    Qualifying MS Diagnosis

    Document a qualifying multiple sclerosis indication for the requested therapy.

    • Relapsing form of multiple sclerosis, including relapsing-remitting MS and secondary progressive MS when the member continues to experience relapses

    Clinical Background

    Ocrelizumab products, including Ocrevus and Ocrevus Zunovo, are used to treat multiple sclerosis, including relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. The policy also permits coverage for clinically isolated syndrome. Coverage is subject to the applicable clinical criteria, prior authorization, and prescribing by or consultation with a neurologist.

    Definitions

    Relapsing Forms of Multiple Sclerosis
    Clinically isolated syndromeA relapsing form of multiple sclerosis in adults.
    Relapsing-remitting diseaseA relapsing form of multiple sclerosis in adults.
    Active secondary progressive diseaseA relapsing form of multiple sclerosis in adults.
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyOcrevus and Ocrevus Zunovo (ocrelizumab) Coverage Criteria
    Policy CodePolicy 02-2026
    Change TypeNo material clinical or coverage change
    Effective DateJun 26, 2026
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required for the requested therapy.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation TherapyProvider Requirements and Action ItemsClinical BackgroundDefinitions

    Authorization of 12 months may be granted for treatment of primary progressive multiple sclerosis.

    Primary progressive MS diagnosis: Member has primary progressive multiple sclerosis.

    Authorization period is 12 months.

  1. Clinically isolated syndrome of multiple sclerosis
  2. Primary progressive multiple sclerosis
  3. Documentation Required

    Continuation Response

    For continuation authorization, document that the member has an indication listed in Section C and is experiencing disease stability or improvement while receiving OCREVUS.

    Denial Risk

    Avoid Concomitant Disease-Modifying MS Therapy

    Do not use OCREVUS concomitantly with another disease-modifying multiple sclerosis agent, which may result in denial.

    • Ampyra and Nuedexta are not disease-modifying multiple sclerosis agents and are exceptions to this restriction.
    Denial Risk

    Unmet Coverage Criteria

    Coverage requires a policy-addressed indication and satisfaction of all applicable approval criteria. Document the qualifying diagnosis and supporting clinical information for the requested OCREVUS authorization.

    • Relapsing form of multiple sclerosis, including qualifying secondary progressive disease with ongoing relapse
    • Clinically isolated syndrome of multiple sclerosis
    • Primary progressive multiple sclerosis